SciNeuro Pharmaceuticals, a US-based, neuroscience-focused biopharmaceutical company, announced on Friday that it has named Guojun Bu, PhD as its new chief scientific officer.

In the new role, Dr Bu will have overall leadership responsibility for the company's discovery and preclinical research activities, based in Rockville, Maryland, and will drive the translation of the firm's R&D pipeline programs.

Dr Bu has experience of over 30 years in neurodegenerative disease research, therapeutic discovery, and translation. He has served as the chair of the Department of Neuroscience, Mayo Clinic. He has also served in additional position at Mayo, including Mary Lowell Leary professor of Medicine; director of Mayo Clinic Neuroregeneration Lab; and associate director, Mayo Clinic Alzheimer's Disease Research Center. He has held the position of a professor of Cell Biology and Neuroscience at the Washington University School of Medicine in St. Louis. He has worked as a founding editor and editor-in-chief for Molecular Neurodegeneration. He is also an associate editor for Science Advances and is on the Advisory Board for Neuron.